Tau aggregation and its interplay with amyloid-β
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Neurofibrillary tangles and amyloid plaques constitute the hallmark brain lesions of Alzheimer's disease (AD) patients. Tangles are composed of fibrillar aggregates of the microtubule-associated protein tau, and plaques comprise fibrillar forms of a proteolytic cleavage product, amyloid-β (Aβ). Although plaques and tangles are the end-stage lesions in AD, small oligomers of Aβ and tau are now receiving increased attention as they are shown to correlate best with neurotoxicity. One key question of debate, however, is which of these pathologies appears first and hence is upstream in the pathocascade. Studies suggest that there is an intense crosstalk between the two molecules and, based on work in animal models, there is increasing evidence that Aβ, at least in part, exerts its toxicity via tau, with the Src kinase Fyn playing a crucial role in this process. In other experimental paradigms, Aβ and tau have been found to exert both separate and synergistic modes of toxicity. The challenge, however, is to integrate these different scenarios into a coherent picture. Furthermore, the ability of therapeutic interventions targeting just one of these molecules, to successfully neutralize the toxicity of the other, needs to be ascertained to improve current therapeutic strategies, such as immunotherapy, for the treatment of AD. Although this article is not intended to provide a comprehensive review of the currently pursued therapeutic strategies, we will discuss what has been achieved by immunotherapy and, in particular, how the inherent limitations of this approach can possibly be overcome by novel strategies that involve single-chain antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51],”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of glial cells may provide a link between the initial Aβ aggregation and the later development of tau aggregates,40”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“It is evident that crosstalk between Aβ and tau can significantly influence toxicity; increased Aβ production results in NFT formation in FAD and Down Syndrome, while there is also evidence to show that tau increases Aβ-associated toxicity (particularly synaptotoxcity), suggesting that the presence of both pathological features are important to replicate the toxicity that occurs in human AD [106].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“1 3 There is considerable debate regarding which Aβ species is the most neurotoxic, with increasing evidence suggesting that it is the small molecular weight oligomers that correlate best with disease [8, 52, 62, 67].”
BackgroundRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Furthermore, more than 20 pathogenic mutations have been identified in APP and several of these, including the V717I ‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], the K670D/M671L ‘Swedish’ mutation [65] and the E693G ‘Arctic’ mutation [69], have been expressed in transgenic mice.”
BackgroundTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 2×
“Evidently, no mouse model is capable of fully recapitulating the neuropathological spectrum of the disease [72].”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · cited 1×
“connected brain regions [15].”
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cited by
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
“It is evident that crosstalk between Aβ and tau can significantly influence toxicity; increased Aβ production results in NFT formation in FAD and Down Syndrome, while there is also evidence to show that tau increases Aβ-associated toxicity (particularly synaptotoxicity), suggesting that the presence of both pathologic…”
BackgroundArendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 495
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
“A multilevel connection between deposits and soluble oligomers of Ab and progressive phosphorylation of the Tau protein is a strong argument for the validity and integrity of both theories in the development of AD [49].”
Backgroundde Wolf, F., Ghanbari, M., Licher, S., McRae-McKee, K., Gras, L., Weverling, G. J., Wermeling, P., Sedaghat, S., Ikram, M. K., Waziry, R., et al. (2020) · Brain · doi:10.1093/brain/awaa054 · Cited by 324
“Alzheimer’s disease is defined by its underlying pathological process of amyloid-b plaques and neuro-fibrillary tau tangle formation in the brain, accompanied by progressive neuronal and synaptic loss (Braak et al. , 2006; Serrano-Pozo et al. , 2011; Nisbet et al. , 2015).”
Sengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 293
“At synaptic level, AβO can activate extra-synaptic glutamate receptors, N-methyl-D-aspartate receptors (NMDARs), eventually activating AMP-activated protein kinase (AMPK), which in turn, phosphorylates dendritic tau causing its dissociation from microtubule and aggregation (Nisbet et al., 2015).”
BackgroundRole of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
The role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics
Cassidy, L., Fernandez, F., Johnson, J. B., Naiker, M., Owoola, A. G., & Broszczak, D. A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102294 · Cited by 275
Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
Cope, T. E., Rittman, T., Borchert, R. J., Jones, P. S., Vatansever, D., Allinson, K., Passamonti, L., Vazquez Rodriguez, P., Bevan-Jones, W. R., O'Brien, J. T., et al. (2018) · Brain · doi:10.1093/brain/awx347 · Cited by 246
“effects (Nisbet et al., 2015), there is converging evidence”
BackgroundTumminia, A., Vinciguerra, F., Parisi, M., & Frittitta, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113306 · Cited by 249
“It is known that small oligomers of Aβ contribute to the synapto-toxicity and downstream events that lead to the neurodegenerative processes in AD [43,44].”
BackgroundA Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies
Orr, M. E., Sullivan, A. C., & Frost, B. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.011 · Cited by 235
Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease
Sharma, C., Kim, S., Nam, Y., Jung, U. J., & Kim, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094850 · Cited by 234
“Reports also suggest that an aging-mediated reduction in proteasome activity may further promote Aβ and tau accumulation [40,41].”
BackgroundReview of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020381 · Cited by 213
“In the brain of AD patients, tau is hyperphosphorylated at least three folds (molar ratio) higher than that in the normal brain [25,27].”
BackgroundHladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Song, C., Shieh, C.-H., Wu, Y.-S., Kalueff, A., Gaikwad, S., & Su, K.-P. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.12.003 · Cited by 187
Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187
“Alzheimer’s disease is characterized by the deposition of amyloid-b as amyloid plaques and hyperphosphorylated tau as neurofibrillary tangles, together with synaptic and neuronal degeneration (Ising et al., 2015; Nisbet et al., 2015).”
Self-citationEffects of in vivo conditions on amyloid aggregation
Owen, M. C., Gnutt, D., Gao, M., Wärmländer, S. K. T. S., Jarvet, J., Gräslund, A., Winter, R., Ebbinghaus, S., & Strodel, B. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00034d · Cited by 182
The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.
Jellinger, K. A., Alafuzoff, I., Attems, J., Beach, T. G., Cairns, N. J., Crary, J. F., Dickson, D. W., Hof, P. R., Hyman, B. T., Jack, C. R., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1407-2 · Cited by 171
Finley, J. W., & Gao, S. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04398 · Cited by 159
Tan, S. H., Karri, V., Tay, N. W. R., Chang, K. H., Ah, H. Y., Ng, P. Q., Ho, H. S., Keh, H. W., & Candasamy, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.101 · Cited by 146
Oral Microbiota and Alzheimer’s Disease: Do All Roads Lead to Rome?
Sureda, A., Daglia, M., Argüelles Castilla, S., Sanadgol, N., Fazel Nabavi, S., Khan, H., Belwal, T., Jeandet, P., Marchese, A., Pistollato, F., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104582 · Cited by 143
Tau: From research to clinical development
Holtzman, D. M., Carrillo, M. C., Hendrix, J. A., Bain, L. J., Catafau, A. M., Gault, L. M., Goedert, M., Mandelkow, E., Mandelkow, E., Miller, D. S., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.018 · Cited by 139
“[40] Nisbet RM, Polanco JC, Ittner LM, Gotz J.”
Grova, N., Schroeder, H., Olivier, J. L., & Turner, J. D. (2019) · International Journal of Genomics · doi:10.1155/2019/2085496 · Cited by 158
“Tau is a neuronal signalling and axonal transport protein that is functionally modulated by phosphorylation [93, 94].”
BackgroundPathology and hippocampal atrophy in Alzheimer's disease
Halliday, G. M. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30343-5 · Cited by 149
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Teixeira, J. P., de Castro, A. A., Soares, F. V., da Cunha, E. F. F., & Ramalho, T. C. (2019) · Molecules · doi:10.3390/molecules24234410 · Cited by 121
“Research lines co cerning depo its and oligomers, along with the progressive phosphorylation of th tau protein, raise insights into the dev lopment and evoluti n of AD, bringing bout advances in the discovery of novel remediation strategies [40].”
BackgroundNewsholme, E. A., Newsholme, P., & Curi, R. (1987) · PubMed · Cited by 132
Gomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125
Marchitelli, R., Aiello, M., Cachia, A., Quarantelli, M., Cavaliere, C., Postiglione, A., Tedeschi, G., Montella, P., Milan, G., Salvatore, M., et al. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.04.048 · Cited by 124
“These are primarily derived from structural magnetic resonance imaging (MRI) of the hippocampus (Sarazin et al., 2010) and from analysis of cerebral spinal fluid (CSF) amyloid β (Aβ) or tau protein concentrations (Nisbet et al., 2015; Nordberg, 2010).”
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
“These Aβ deposits inhibit synaptic dysfunction by binding to synaptic receptors (Nisbet et al., 2015).”
BackgroundKlavins, K., Koal, T., Dallmann, G., Marksteiner, J., Kemmler, G., & Humpel, C. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.05.003 · Cited by 110
“dependent of b-amyloid [2] but recent evidence indicates that both proteins interact [3].”
BackgroundInflammation and Alzheimer’s Disease: Mechanisms and Therapeutic Implications by Natural Products
Rather, M. A., Khan, A., Alshahrani, S., Rashid, H., Qadri, M. M., Rashid, S., Alsaffar, R. M., Kamal, M. A., & Rehman, M. U. (2021) · Mediators of Inflammation · doi:10.1155/2021/9982954 · Cited by 120
“Researchers postulated that continuous immune response is linked with neurodegeneration as well as the acceleration of both A β and NFT lesions and supports the insight into initial incidents of A β lesions followed by the progression of NFTs [5, 6].”
Modeling and Targeting Alzheimer’s Disease With Organoids
Papaspyropoulos, A., Tsolaki, M., Foroglou, N., & Pantazaki, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00396 · Cited by 106
“Ab peptide accumulation may synergize with tau-related NFT formation to contribute to AD manifestation, as indicated by a number of studies (Nisbet et al., 2015).”
BackgroundVascular Hypothesis of Alzheimer Disease: Topical Review of Mouse Models
Scheffer, S., Hermkens, D. M. A., van der Weerd, L., de Vries, H. E., & Daemen, M. J. A. P. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.311911 · Cited by 102
The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System
Joppe, K., Roser, A.-E., Maass, F., & Lingor, P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00015 · Cited by 102
“Mostly, it is located in axons and sometimes in dendrites (Nisbet et al., 2015).”
BackgroundFaucher, P., Mons, N., Micheau, J., Louis, C., & Beracochea, D. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00245 · Cited by 100
Aβ plaque-selective NIR fluorescence probe to differentiate Alzheimer's disease from tauopathies
Rajasekhar, K., Narayanaswamy, N., Murugan, N. A., Viccaro, K., Lee, H.-G., Shah, K., & Govindaraju, T. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.06.030 · Cited by 97
“Misfolded Aβ peptide (predominantly Aβ42) and hyperphosphorylated tau protein undergo aggregation to form insoluble Aβ plaques and NFTs, respectively in the brain, which are the hallmarks of AD (Hamley et al., 2012; Nisbet et al., 2015; Iqbal et al., 2014).”
BackgroundEsmieu, C., Guettas, D., Conte‐Daban, A., Sabater, L., Faller, P., & Hureau, C. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b00995 · Cited by 110
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Park, D., Kim, J., Kim, H. J., Lee, D., Lee, D. S., Yoon, D. S., & Hwang, K. S. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112505 · Cited by 101
Kumar, N., Kumar, V., Anand, P., Kumar, V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 105
Shin, W. S., Di, J., Cao, Q., Li, B., Seidler, P. M., Murray, K. A., Bitan, G., & Jiang, L. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0541-9 · Cited by 92
“The relationships among Aβ, tau, and neurodegeneration in AD are not fully understood [4, 5].”
BackgroundLau, D. H. W., Hogseth, M., Phillips, E. C., O’Neill, M. J., Pooler, A. M., Noble, W., & Hanger, D. P. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0317-4 · Cited by 90
Structural Plasticity of the Hippocampus in Neurodegenerative Diseases
Weerasinghe-Mudiyanselage, P. D. E., Ang, M. J., Kang, S., Kim, J., & Moon, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063349 · Cited by 101
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
“Current evidence suggests that oligomers within the brain parenchyma are the main culprits leading to neurodegeneration (Nisbet et al., 2015, McIntee et al., 2016, Hladky and Barrand, 2018).”
BackgroundThe informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
“Normal forms of tau function as a regulator of axonal remodeling are actively regulated and produced, and extracellular tau has increased production correlating with amount of amyloid plaques [60].”
BackgroundBeyond Fmoc: a review of aromatic peptide capping groups
Martin, A. D., & Thordarson, P. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02539a · Cited by 91
Oxidative stress: A target to treat Alzheimer's disease and stroke
Briyal, S., Ranjan, A. K., & Gulati, A. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105509 · Cited by 94
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases
Rozpędek-Kamińska, W., Siwecka, N., Wawrzynkiewicz, A., Wojtczak, R., Pytel, D., Diehl, J. A., & Majsterek, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062108 · Cited by 84
“The main hallmarks of AD are extracellular deposition of senile plaques and intracellular aggregation of neurofibrillary tangles (NFTs) within the brain tissue [23].”
BackgroundRole of free radicals in human inflammatory diseases
Biswas, S., Das, R., & Banerjee, E. R. (2017) · AIMS Biophysics · doi:10.3934/biophy.2017.4.596 · Cited by 104
“Alzheimer’s disease (AD) is a neurodegenerative condition characterized by the formation of amyloid-β plaques, aggregated and hyperphosphorylated tau protein, activated microglia and neuronal cell death, ultimately leading to progressive dementia [177,178].”
Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 82
“Two distinct types of aggregates are the primary neuropathological indicators of AD [37].”
BackgroundOlajide, O. J., Yawson, E. O., Gbadamosi, I. T., Arogundade, T. T., Lambe, E., Obasi, K., Lawal, I. T., Ibrahim, A., & Ogunrinola, K. Y. (2017) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2017.02.010 · Cited by 79
Janowicz, P. W., Leinenga, G., Götz, J., & Nisbet, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45577-2 · Cited by 76
Self-citationRodriguez, G. A., Barrett, G. M., Duff, K. E., & Hussaini, S. A. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000851 · Cited by 77
Shamsi, A., Mohammad, T., Anwar, S., Alajmi, M. F., Hussain, A., Hassan, M. I., Ahmad, F., & Islam, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.134 · Cited by 73
Lee, H.-Y., Fan, S.-J., Huang, F.-I., Chao, H.-Y., Hsu, K.-C., Lin, T. E., Yeh, T.-K., Lai, M.-J., Li, Y.-H., Huang, H.-L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00151 · Cited by 71
Sales, T. A., Prandi, I. G., de Castro, A. A., Leal, D. H. S., da Cunha, E. F. F., Kuča, K., & Ramalho, T. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081829 · Cited by 75
“The relationship between aggregates and soluble oligomers of Aβ and gradual phosphorylation of the tau protein is a necessary discussion to support theories referring to the development and evolution of AD [56].”
BackgroundSphingolipid-Enriched Extracellular Vesicles and Alzheimer’s Disease: A Decade of Research
Dinkins, M. B., Wang, G., & Bieberich, E. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160567 · Cited by 72
Zhou, H., Tai, J., Xu, H., Lu, X., & Meng, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01035 · Cited by 74
“…most convincing hypothesis of AD pathophysiological 2 September 2019 | Volume 10 | Article 1035Frontiers in Pharmacology | www.frontiersin.org mechanism is the accumulation of extracellular amyloid-β (Aβ) and formation of neurofibrillary hyperphosphorylated tau (p-tau) tangle (Nisbet et al., 2015).”
BackgroundAboelwafa, H. R., El-kott, A. F., Abd‐Ella, E. M., & Yousef, H. N. (2020) · Brain Sciences · doi:10.3390/brainsci10090628 · Cited by 82
Cai, B., Ye, S., Wang, T., Wang, Y., Li, J., Zhan, J.-X., & Shen, G.-M. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.215260 · Cited by 73
“Hyperphosphorylation of tau protein inhibits binding to microtubules and destabilizes the cytoskeletal system, causing the formation of double helix fibers, eventually leading to neuronal death (Hanger et al., 2009; George et al., 2014; Nisbet et al., 2015).”
BackgroundKim, S.-H., Cho, Y.-S., Kim, Y., Park, J., Yoo, S.-M., Gwak, J., Kim, Y., Gwon, Y., Kam, T.-I., & Jung, Y.-K. (2023) · Autophagy · doi:10.1080/15548627.2023.2181614 · Cited by 60
“Given that highly phosphorylated MAPT oligomers and aggregates cause neurodegeneration and often function as downstream mediators of Aβ signaling in AD [47,48], we assessed the role of MAPT in the endolysosomal axis.”
BackgroundPositive Feedback Loops in Alzheimer’s Disease: The Alzheimer’s Feedback Hypothesis
Doig, A. J. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180583 · Cited by 62
Safarizadeh, H., & Garkani‐Nejad, Z. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.11.019 · Cited by 62
The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells
Cai, W., Wu, T., & Chen, N. (2023) · Biomolecules · doi:10.3390/biom13020313 · Cited by 61
“According to one of the previous studies, Aβ deposition occurs before the formation of Tau fibrillary tangles, which is assumed to be responsible for the pathological accumulation of Tau and Tau-mediated neurodegeneration [42].”
BackgroundThe role of CD2AP in the Pathogenesis of Alzheimer's Disease
Tao, Q.-Q., Chen, Y.-C., & Wu, Z.-Y. (2019) · Aging and disease · doi:10.14336/ad.2018.1025 · Cited by 61
“mitochondrial function, abnormal calcium metabolism and altered axonal transport [6-9].”
BackgroundD’Onofrio, G., Nabavi, S. M., Sancarlo, D., Greco, A., & Pieretti, S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210113144703 · Cited by 71
Primary Fibril Nucleation of Aggregation Prone Tau Fragments PHF6 and PHF6*
Smit, F. X., Luiken, J. A., & Bolhuis, P. G. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b07045 · Cited by 61
Thomas, M. H., Pelleïeux, S., Vitale, N., & Olivier, J. L. (2016) · Biochimie · doi:10.1016/j.biochi.2016.07.013 · Cited by 62
SIRT1 as a therapeutic target for Alzheimer’s disease
Wong, S. Y., & Tang, B. L. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0023 · Cited by 61
Tau Toxicity in Neurodegeneration
Liang, S., Wang, Z.-T., Tan, L., & Yu, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02809-3 · Cited by 64
“The interaction between tau and Fyn has the ability to affect the stability of the complex formed by NMDA receptor and postsynaptic density protein 95, which plays a key role in Aβ-induced neurotoxicity [72].”
BackgroundInfluentialResveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials
Drygalski, K., Fereniec, E., Koryciński, K., Chomentowski, A., Kiełczewska, A., Odrzygóźdź, C., & Modzelewska, B. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.09.019 · Cited by 62
Veening-Griffioen, D. H., Ferreira, G. S., van Meer, P. J. K., Boon, W. P. C., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172524 · Cited by 55
“…hallmarks of Alzheimer's disease include (age induced) cognitive impairment (Alzheimer's Association, 2018), decreased levels of neurotransmitters (Francis, 2005), increased neurological markers such as amyloid β plaques and tau tangles (Nisbet et al., 2015) or genetic alterations (Reitz, 2015).”
BackgroundCurrent and Emerging Strategies for Enhancing Antibody Delivery to the Brain
Bajracharya, R., Caruso, A. C., Vella, L. J., & Nisbet, R. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122014 · Cited by 54
“Alzheimer’s disease is histopathologically characterised by the extracellular accumulation of amyloid-β (Aβ) plaques and the intracellular accumulation of pathological tau protein that deposits as neurofibrillary tangles [50,51].”
BackgroundSelf-citationIaccarino, L., La Joie, R., Edwards, L., Strom, A., Schonhaut, D. R., Ossenkoppele, R., Pham, J., Mellinger, T., Janabi, M., Baker, S. L., et al. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhaa184 · Cited by 54
“W-scores distribution is analogous to Z-scores distribution and can thus be evaluated considering properties of the Gaussian curve (La Joie et al. 2012; Ossenkoppele et al. 2015; van Loenhoud et al. 2017).”
BackgroundMethodDissel, S., Klose, M., Donlea, J., Cao, L., English, D., Winsky-Sommerer, R., van Swinderen, B., & Shaw, P. J. (2017) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2016.09.001 · Cited by 53
“A crosstalk between Aβ and tau has been demonstrated such that each may not only exert their toxic effects independently but also interact synergistically (Nisbet et al., 2015).”
BackgroundFluorescence Chemicals To Detect Insoluble and Soluble Amyloid-β Aggregates
Lee, D.-H., Kim, S., Kim, H. Y., & Kim, Y. S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00199 · Cited by 54
Metal-organic frameworks: A promising option for the diagnosis and treatment of Alzheimer's disease
Tajahmadi, S., Molavi, H., Ahmadijokani, F., Shamloo, A., Shojaei, A., Sharifzadeh, M. S., Rezakazemi, M., Fatehizadeh, A., Aminabhavi, T. M., & Arjmand, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.002 · Cited by 54
Nisbet, R. M., & Götz, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179907 · Cited by 61
Self-citationAlzheimer’s Disease: A Molecular View of β-Amyloid Induced Morbific Events
Asik, R. M., Suganthy, N., Aarifa, M. A., Kumar, A., Szigeti, K., Máthé, D., Gulyás, B. Z., Archunan, G., & Padmanabhan, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091126 · Cited by 56
Alzheimer disease: modeling an Aβ-centered biological network
Campion, D., Pottier, C. P., Nicolas, G., Guennec, K. L., & Rovelet‐Lecrux, A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.38 · Cited by 61
Depression in Alzheimer’s Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?
Elsworthy, R. J., & Aldred, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180780 · Cited by 74
“SSRIs may also help by reducing synergistic toxic effects of A (cid:2) and hyperphosphorylated tau and the associated synaptic and neuronal dysfunction seen in people with AD [121, 122].”
Coşacak, M. İ., Bhattarai, P., Bocova, L., Dzewas, T., Mashkaryan, V., Papadimitriou, C., Brandt, K., Hollak, H., Antos, C. L., & Kızıl, Ç. (2017) · Scientific Reports · doi:10.1038/s41598-017-13311-5 · Cited by 57
Arendash, G. W., Cao, C., Abulaban, H., Baranowski, R., Wisniewski, G., Becerra, L. R., Andel, R., Lin, X., Zhang, X., Wittwer, D., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190367 · Cited by 55
“Oligomeric tau, although downstream from A in AD pathogenesis, may be the main propagator of AD [9, 28], and increasing evidence suggests -synuclein aggregation plays a role in AD as well [29, 30].”
BackgroundTau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Aillaud, I., & Funke, S. A. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01230-7 · Cited by 53
“Recent data suggest that Tau pathology is not simply a downstream process of Aβ aggregation (Nisbet et al. 2015; Pourhamzeh et al. 2021).”
BackgroundOxidative Stress in Alzheimer’s Disease: Molecular Hallmarks of Underlying Vulnerability
Uddin, M. S., & Kabir, M. T. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_5 · Cited by 52
The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease
Park, S.-H., Lee, E.-H., Kim, H.-J., Jo, S., Lee, S., Seo, S. W., Park, H.-H., Koh, S.-H., & Lee, J.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-92101-6 · Cited by 48
Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow�, E., Horn, A. H. C., Sticht, H., Malhis, M., Will, N., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167432 · Cited by 54
Curcumin Scaffold as a Multifunctional Tool for Alzheimer’s Disease Research
Yang, H., Zeng, F., Luo, Y., Zheng, C., Ran, C., & Yang, J. (2022) · Molecules · doi:10.3390/molecules27123879 · Cited by 55
Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease
Rosen, R. F., Tomidokoro, Y., Farberg, A. S., Dooyema, J., Ciliax, B., Preuss, T. M., Neubert, T. A., Ghiso, J. A., LeVine, H., & Walker, L. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.019 · Cited by 46
Alzheimer's disease vaccine development: A new strategy focusing on immune modulation
Marciani, D. J. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.08.008 · Cited by 50
Recombinant Antibody Fragments for Neurodegenerative Diseases
Manoutcharian, K., Pérez-Garmendia, R., & Gevorkian, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x01666160930121647 · Cited by 51
Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β
Sen, T., Saha, P., & Sen, N. (2018) · Science Signaling · doi:10.1126/scisignal.aao6765 · Cited by 45
Fernandes, R. M., Corrêa, M. G., Aragão, W. A. B., Nascimento, P. C., Cartágenes, S. D. C., Rodrigues, C. A., Sarmiento, L. F., Monteiro, M. C., Maia, C. D. S. F., Lopez, M. E. C., et al. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111139 · Cited by 53
Roda, A. R., Esquerda-Canals, G., Martí, J., & Villegas, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100944 · Cited by 55
“This is in consonance with the extensively reported downstream relation between both, amyloid and tau pathologies [54].”
Metadata
- Authors
- Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J.
- Affiliations
- The University of Queensland (AU)
- UNSW Sydney (AU)
- Corresponding author
- Nisbet, Rebecca M.
- Götz, Jürgen
- Venue
- Acta Neuropathologica
- Published
- 2014-12-10
- Volume
- 129
- Issue
- 2
- Pages
- 207-220
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC4305093
- OpenAlex
- W2007787335
- Cited by
- 359
- References
- 114
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 20 · 2023: 22 · 2022: 49 · 2021: 41 · 2020: 33 · 2019: 44 · 2018: 32 · 2017: 26 · 2016: 31 · 2015: 14
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Australian Research Council (DP13300101932)
- National Health and Medical Research Council (1003150, 1037746)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau aggregation, amyloid-beta, Alzheimer's disease, neurofibrillary tangles, amyloid plaques, tau oligomers, amyloid-beta oligomers, neurotoxicity, Fyn, immunotherapy, single-chain antibody, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Humans, Synapses, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.